Synergistic Antitumor Activity of Regorafenib and Rosuvastatin in Colorectal Cancer

Overview

Journal Front Pharmacol

Date 2023 May 4

PMID 37138847

Authors

Tao Yuan

Ruilin Wu

Weihua Wang

Yue Liu

Wencheng Kong

Bo Yang

Qiaojun He

Hong Zhu

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is one of the most prevalent life-threatening malignant tumors with high incidence and mortality. However, the efficacy of current therapeutic regimens is very limited. Regorafenib has been approved for second- or third-line treatment of patients who are refractory to standard chemotherapy diagnosed with metastatic colorectal cancer, but its clinical efficacy needs to be further improved. Accumulating evidence demonstrates that statins also possess potent anticancer activities. However, whether regorafenib and statins pose synergistic anticancer effects in colorectal cancer is still unclear. Sulforhodamine B (SRB) assays were applied to evaluate the anti-proliferative activity of regorafenib or/and rosuvastatin , and immunoblotting analysis were applied to detect the effects of regorafenib/rosuvastatin combined treatment on mitogen-activated protein kinase (MAPK) signaling and apoptosis-related proteins. MC38 tumors were applied to investigate the synergistic anticancer effects of regorafenib in combination with rosuvastatin . We found that regorafenib in combination with rosuvastatin exerted significant synergistic inhibition against colorectal cancer growth and . Mechanistically, regorafenib and rosuvastatin combination synergistically suppressed MAPK signaling, a crucial signaling pathway promoting cell survival, as indicated by the reduction of phosphorylated MEK/ERK. In addition, regorafenib in combination with rosuvastatin synergistically induced the apoptosis of colorectal cancer and . Our study demonstrated the synergistic anti-proliferative and pro-apoptotic effects of regorafenib/rosuvastatin combined treatment in colorectal cancer and might potentially be evaluated as a novel combination regimen for clinical treatment of colorectal cancer.

Citing Articles

The Effect of Statin Usage on Survival in Metastatic Colorectal Cancer Patients Receiving Regorafenib.

Erdat E, Kavak E, Yalciner M, Utkan G In Vivo. 2024; 38(6):2921-2927.

PMID: 39477441 PMC: 11535903. DOI: 10.21873/invivo.13774.

Obesity-Associated Colorectal Cancer.

Gonzalez-Gutierrez L, Motino O, Barriuso D, de la Puente-Aldea J, Alvarez-Frutos L, Kroemer G Int J Mol Sci. 2024; 25(16).

PMID: 39201522 PMC: 11354800. DOI: 10.3390/ijms25168836.

Interleukin-6 serves as a critical factor in various cancer progression and therapy.

Mohamed A, Ahmed A, Al Abdulmonem W, Olegovich Bokov D, Shafie A, Al-Hetty H Med Oncol. 2024; 41(7):182.

PMID: 38900329 DOI: 10.1007/s12032-024-02422-5.

Pharmacokinetic interaction between regorafenib and atorvastatin in rats.

Szkutnik-Fiedler D, Szalek E, Otto F, Czyrski A, Karazniewicz-Lada M, Wolc A Pharmacol Rep. 2024; 76(5):1184-1195.

PMID: 38632186 PMC: 11387447. DOI: 10.1007/s43440-024-00570-z.

The role of gut microbiota and drug interactions in the development of colorectal cancer.

Wu J, Xia C, Liu C, Zhang Q, Xia C Front Pharmacol. 2023; 14:1265136.

PMID: 37680706 PMC: 10481531. DOI: 10.3389/fphar.2023.1265136.

References

Yeagle P . Unraveling a mystery: Why human cells require cholesterol. Sci Adv. 2022; 8(37):eade5927. PMC: 9473577. DOI: 10.1126/sciadv.ade5927. View

Iannelli F, Roca M, Lombardi R, Ciardiello C, Grumetti L, De Rienzo S . Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. J Exp Clin Cancer Res. 2020; 39(1):213. PMC: 7545949. DOI: 10.1186/s13046-020-01723-7. View

Gobel A, Rauner M, Hofbauer L, Rachner T . Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. Biochim Biophys Acta Rev Cancer. 2020; 1873(2):188351. DOI: 10.1016/j.bbcan.2020.188351. View

Kanukula R, Salam A, Rodgers A, Kamel B . Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. Clin Pharmacokinet. 2021; 60(2):165-175. DOI: 10.1007/s40262-020-00978-9. View

Xie Y, Chen Y, Fang J . Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1):22. PMC: 7082344. DOI: 10.1038/s41392-020-0116-z. View

Demetri G, Reichardt P, Kang Y, Blay J, Rutkowski P, Gelderblom H . Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):295-302. PMC: 3819942. DOI: 10.1016/S0140-6736(12)61857-1. View

Stefani C, Miricescu D, Stanescu-Spinu I, Nica R, Greabu M, Ripszky Totan A . Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?. Int J Mol Sci. 2021; 22(19). PMC: 8508474. DOI: 10.3390/ijms221910260. View

Arai H, Battaglin F, Wang J, Lo J, Soni S, Zhang W . Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019; 81:101912. PMC: 7491975. DOI: 10.1016/j.ctrv.2019.101912. View

Luchtel R, Bhagat T, Pradhan K, Jacobs Jr W, Levine M, Verma A . High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. Proc Natl Acad Sci U S A. 2020; 117(3):1666-1677. PMC: 6983418. DOI: 10.1073/pnas.1908158117. View

10.

Biller L, Schrag D . Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021; 325(7):669-685. DOI: 10.1001/jama.2021.0106. View

11.

Yang Z, Su Z, DeWitt J, Xie L, Chen Y, Li X . Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy. EBioMedicine. 2017; 19:49-59. PMC: 5440603. DOI: 10.1016/j.ebiom.2017.04.017. View

12.

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

13.

Mehibel M, Ortiz-Martinez F, Voelxen N, Boyers A, Chadwick A, Telfer B . Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters. Sci Rep. 2018; 8(1):16804. PMC: 6235971. DOI: 10.1038/s41598-018-35103-1. View

14.

Iannelli F, Lombardi R, Milone M, Pucci B, De Rienzo S, Budillon A . Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. Recent Pat Anticancer Drug Discov. 2017; 13(2):184-200. DOI: 10.2174/1574892812666171129141211. View

15.

McGregor G, Campbell A, Fey S, Tumanov S, Sumpton D, Blanco G . Targeting the Metabolic Response to Statin-Mediated Oxidative Stress Produces a Synergistic Antitumor Response. Cancer Res. 2019; 80(2):175-188. DOI: 10.1158/0008-5472.CAN-19-0644. View

16.

Cao S, Zhen Y . Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol. 1989; 24(3):181-6. DOI: 10.1007/BF00300240. View

17.

Li L, Cui N, Hao T, Zou J, Jiao W, Yi K . Statins use and the prognosis of colorectal cancer: a meta-analysis. Clin Res Hepatol Gastroenterol. 2021; 45(5):101588. DOI: 10.1016/j.clinre.2020.101588. View

18.

Argiles G, Saunders M, Rivera F, Sobrero A, Benson 3rd A, Guillen Ponce C . Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Eur J Cancer. 2015; 51(8):942-9. DOI: 10.1016/j.ejca.2015.02.013. View

19.

Sanoff H, Goldberg R, Ivanova A, OReilly S, Kasbari S, Kim R . Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. 2018; 124(15):3118-3126. DOI: 10.1002/cncr.31552. View

20.

Damon L, Cadman E . Advances in rational combination chemotherapy. Cancer Invest. 1986; 4(5):421-44. DOI: 10.3109/07357908609017522. View